RESEARCH ARTICLE

ELK1 has a dual activating and repressive role in human embryonic stem cells [version 1; peer review: 2 approved with reservations]

Ian Prise id1, Andrew D. Sharrocks id2

id1Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PT, UK
id2Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PT, UK

Abstract

Background: The ERK MAPK pathway plays a pivotal role in regulating numerous cellular processes during normal development and in the adult but is often deregulated in disease scenarios. One of its key nuclear targets is the transcription factor ELK1, which has been shown to play an important role in controlling gene expression in human embryonic stem cells (hESCs). ELK1 is known to act as a transcriptional activator in response to ERK pathway activation but repressive roles have also been uncovered, including a putative interaction with the PRC2 complex.

Methods: Here we probe the activity of ELK1 in hESCs by using a combination of gene expression analysis in hESCs and during differentiation following ELK1 depletion and also analysis of chromatin occupancy of transcriptional regulators and histone mark deposition that accompany changes in gene expression.

Results: We find that ELK1 can exert its canonical activating activity downstream from the ERK pathway but also possesses additional repressive activities. Despite its co-binding to PRC2 occupied regions, we could not detect any ELK1-mediated repression at these regions. Instead, we find that ELK1 has a repressive role at a subset of co-occupied SRF binding regions. This latter repressive role appears not to be exerted through competition with MRTF family co-activators.

Conclusions: ELK1 should therefore be viewed as a dichotomous transcriptional regulator that can act through SRF to generate both activating and repressing properties at different genomic loci.

Keywords

ELK1, repression, embryonic stem cells
Corresponding author: Andrew D. Sharrocks (andrew.d.sharrocks@manchester.ac.uk)

Author roles: Prise I: Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; Sharrocks AD: Conceptualization, Formal Analysis, Funding Acquisition, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was funded by the A*STAR programme for PhD studentships with Manchester and Singapore for IP and a grant from the Wellcome Trust (grant 103857) to ADS.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Prise I and Sharrocks AD. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Prise I and Sharrocks AD. ELK1 has a dual activating and repressive role in human embryonic stem cells [version 1; peer review: 2 approved with reservations] Wellcome Open Research 2019, 4:41 (https://doi.org/10.12688/wellcomeopenres.15091.1)

First published: 01 Mar 2019, 4:41 (https://doi.org/10.12688/wellcomeopenres.15091.1)
Introduction

*In vitro* studies on human embryonic stem cells are an important step in understanding the molecular basis to human development. Cultured human embryonic stem cells (hESCs) require FGF2-mediated signalling through the ERK pathway to maintain their pluripotent state (Lanner & Rossant, 2010). More recent studies indicate that an earlier ERK pathway-independent state can be achieved whereby ERK pathway suppression is a key event in driving this transition (Theunissen et al., 2014). This earlier state is equivalent to the mouse ESC naïve ground state that is thought to represent the pre-implantation epiblast. Nevertheless, understanding the role of the ERK pathway in hESCs remains an important goal. Some of the best characterised targets of the ERK MAPK signalling pathway are the E-twenty six (ETS) proteins, which are nuclear transcription factors and as such can directly convert ERK pathway signalling events into changes to the cellular transcriptome (Yang et al., 2013). One of the best-studied ETS transcription factors in this context is ELK1, which is multi-phosphorylated by ERK in its transactivation domain, thereby converting it into a potent transcriptional activator (Cruzalegui et al., 1999; Gille et al., 1995; Janneke et al., 1993; Marais et al., 1993; Mylona et al., 2016). Recently, ERK was shown to exhibit a high degree of overlap with ELK1 binding to chromatin in hESCs, and this association was observed at active chromatin regions, consistent with an activating function for ELK1 (Göke et al., 2013). However, unexpectedly, ELK1 was also found to bind to a different set of genomic loci, which were co-occupied with PRC2 complex components and marked with repressive histone tail modifications. This observation is suggestive of a repressive role in this context, and a model was proposed in which ELK1 promotes PRC2 complex recruitment and hence transcriptional repression. ELK1 has previously been associated with transcriptional repression through its ability to recruit the SIN3A complex in response to growth factor signalling (Yang et al., 2001) and the recruitment of HDAC2 following its modification with SUMO (Yang & Sharrocks, 2004). SIN3A complex recruitment is associated with inactivation of ELK1 following activation by ERK-mediated phosphorylation, whereas SUMO-mediated HDAC2 recruitment is thought to maintain ELK1 in a transcriptionally repressive state prior to growth factor stimulation. A further repressive mechanism has been associated with ELK1, whereby it competes for binding of SRF with the potent transcriptional co-activator myocardin and other MRTF family members (Wang et al., 2004; Zaromytidou et al., 2006). More recently, a similar repressive role for ELK1 was observed, but instead of competing for co-activator binding to SRF, ELK1 competed with other activating transcription factors from the ETS family for directly binding to their recognition sites on DNA (Odrowaz & Sharrocks, 2012). ELK1 therefore appears to be a bifunctional transcription factor that acts as an ERK-dependent activator through its binding partner SRF but also has numerous other repressive roles.

Here we extended the analysis of ELK1 function in hESCs, first exploring the relationship between ELK1 and the PRC2 complex, and then its activity through its known binding partner SRF. Despite ELK1 and PRC2 co-occupying a large number of genomic regions, we were unable to uncover evidence to support a repressive role of ELK1 in this context. However, unexpectedly, we were able to uncover a repressive role for ELK1 in the context of a subset of SRF-bound regulatory regions. This repressive role appeared distinct from a simple competition model for SRF binding by the co-activator MRTFA. ELK1 therefore possesses both activating and repressive functions in hESCs, directed through its regulatory partner protein SRF.

Results

Functional interplay between ELK1 and PRC2

Previous studies demonstrated that ELK1 occupies two distinct sets of genomic loci in H1-hESCs (Göke et al., 2013). One set was associated with co-binding with SRF, a configuration which is usually associated with transcriptional activation. However, the second set of loci exhibited co-localisation with members of the repressive PRC2 complex, hence suggesting a role in transcriptional repression. As these conclusions were based on the analysis of promoter-proximal ELK1 binding sites, we re-analysed the chromatin immunoprecipitation sequencing (ChIP-seq) data to establish whether these patterns could be observed in a genome-wide manner. Initially we focussed on the co-association with the PRC2 complex, and segregated ELK1 regions according to whether co-binding of the PRC2 complex subunit SUZ12 could be identified (ELK1+SUZ12) or not (ELK1-SUZ12). A significant overlap in ELK1 and SUZ12 binding regions was observed (108 regions; hypergeometric p-value = 7.4x10^{-3}), although the majority of ELK1 binding peaks showed no overlap (Figure 1A). Next, we asked whether the two classes of ELK1 binding regions showed differences in co-association with the ELK1 binding partner SRF and a variety of histone marks that are characteristic of transcriptional repression or activation. The ELK1+SUZ12 binding loci were enriched for SUZ12 and EZH2 binding and for the H3K27me3 histone modification, suggesting repressed regions of chromatin (Figure 1B). In contrast, the ELK1-SUZ12 regions showed little co-association with these repressive features and instead high enrichment of SRF binding was observed and co-association with histone marks suggestive of active transcription, H3K9ac, K3K27ac and H3K4me3 (Figure 1C). These “active” sites also showed strong occupancy by its known binding partner, SRF, consistent with a large overlap between ELK1 binding regions when analysed at the individual binding peak level (Figure 1A). These data point to the existence of an active ELK1+SRF module that lacks PRC2 binding, and a distinct repressive ELK1+SUZ12 module (Figure 1D, E) and are broadly consistent with the models previously proposed using a subset of this data (Göke et al., 2013).

Next, we focussed on the potential repressive role of ELK1 in the context of the ELK1+SUZ12 co-bound regions and sought to establish whether the genes associated with these peaks had potential biological relevance. To address this, we first assigned genes to binding loci with HOMER (Heinz et al., 2010), using the nearest TSS model. We next analysed the biological process gene ontologies (GO) of genes linked to partitioned ELK1 binding loci. ELK1 binding loci overlapping with SUZ12 binding loci (ELK1+SUZ12) were enriched for terms relating to development (Figure 1F). Terms are provided on figshare (Prise, 2019a). This result is consistent with the known function
ELK1 has binding modules either enriched for PRC2 or enriched for active histone marks. (A) Venn diagram showing the intersection of binding regions from genome-wide chromatin immunoprecipitation-sequencing datasets for ELK1, SUZ12 and SRF in H1-hESCs. (B and C) Transcription factor and histone modification tag density profiles in H1-hESCs in a region 2,500 bp to either side of the centre of the ELK1 binding regions. ELK1 binding regions are portioned according to (A) overlapping with SUZ12 binding regions (+SUZ12) or (B) not overlapping with SUZ12 binding regions (-SUZ12). (D and E) Diagrammatic illustration of the ELK1 binding regions associated with co-binding of the repressive PRC2 complex (D) or associated with its binding partner SRF and active regions of chromatin (E). (F and G) Biological function gene ontology terms of genes associated with ELK1 binding loci either overlapping with SUZ12 binding loci (D) or not overlapping with SUZ12 binding loci (E).

Having shown that ELK1+SUZ12 peaks were enriched in development genes, we then identified a set of associated target genes for further study that are induced upon differentiation. We hypothesised that the regulatory regions of these genes would switch from repressed (and PRC2-bound) to active during differentiation. We chose to use retinoic acid (RA), a potent initiator of hESC differentiation. Using the nearest TSS-association model in HOMER, we identified a set of six ELK1+SUZ12-bound genes whose expression increased upon 48–96 hours of treatment with RA (Figure 2A). To understand the role of ELK1 in the context of the repressive modules associated with these genes, we depleted ELK1 using shRNA (Figure 2B, C) and examined the effect on PRC2 occupancy and gene expression in H1-hESCs. ELK1 depletion led to the expected decrease in ELK1 binding in these regions (Figure 2D). However, this was not accompanied with a decrease in SUZ12 binding (Figure 2E), nor did an ELK1 knockdown result in a substantive increase in nearby gene expression (Figure 2F). Thus, although ELK1 co-occupies a set of genomic regions with the PRC2 complex,
Figure 2. ELK1 is not involved in PRC2-mediated repression. (A) Reverse transcription-quantitative PCR (RT-qPCR) analysis of ELK1+SUZ12-bound genes upon 48 and 96 hours of retinoic acid (RA) treatment. Data are shown relative to DMSO-treated cells (taken as 1) and are the average of three independent experiments. Asterisks represent p-value <0.05. (B) RT-qPCR of GAPDH and ELK1 expression after 96 hours of shELK1 knockdown in H1-hESCs. Two different shRNA vectors were tested (plasmid containing shRNA_2 was subsequently used in all experiments). Data are shown relative to control empty plasmid treated cells (taken as 1) and are the average of three independent experiments. Asterisks represent p-value <0.05. (C) Western blot analysis of ELK1 and HDAC1 expression in H1-hESC after 96 hours of treatment with an empty plasmid or a plasmid containing shELK1. (D and E) Chromatin immunoprecipitation-qPCR of ELK1-binding regions for ELK1 (D) or SUZ12 (E) occupancy after 96 hours of treatment with either control empty vector or shELK1. (F) RT-qPCR of ELK1+SUZ12-bound genes after 96 hours of treatment with either control empty vector or shELK1. Data are normalized to GAPDH expression and “control plasmid” (taken as “1”) and are the average of 5 independent experiments, with the exception of the data for ONECUT2 and POU3F2 which are the average of 4 independent experiments.
these results indicate that ELK1 does not appear to have a role in maintaining PRC2 occupancy or in maintaining transcriptional repression through these regions in H1-hESCs. Raw RT-qPCR (Prise, 2019b) and ChIP-qPCR (Prise, 2019c) data are available on figshare.

Functional interplay between ELK1 and SRF

Having shown that ELK1 plays no clear role in PRC2-mediated gene repression, we next returned to the ELK1 module, which preferentially shows enrichment for co-binding of SRF. Of the 710 ELK1-bound regions not found in the ELK1-SUZ12 dataset, 282 (38%) also show SRF co-occupancy (Figure 1A; hypergeometric p-value= 3.2 × 10^{-20}). Notably, there are very few regions co-bound by ELK1, SRF and SUZ12, indicating a clear distinction between regions bound by ELK1 and either SRF or SUZ12. We decided to focus on the role of ELK1 in differentiation to mesoderm as SRF has previously been implicated in this developmental process (Arsenian et al., 1998). An additional advantage of the mesoderm differentiation protocol is that it produces a decrease in pluripotency factors and high expression of the marker gene T after a short 3-day treatment time (Figure 3A–C), and is therefore compatible with a siRNA depletion approach. ELK1 knockdown revealed no general change in expression of pluripotency factors in H1-hESCs (Figure 3D, E), but two mesoderm-marker genes (FOXC1 and HAND2) exhibited increased expression following differentiation to mesoderm, suggesting a potential repressive function in this context (Figure 3F).

To determine possible functional interactions between ELK1 and its known cofactor, SRF, we first identified a set of genes which are located close to potential regulatory regions that are co-bound by ELK1 and SRF. Next, we treated H1-hESCs with either siSRF or siELK1 and then either maintained the hESCs in their pluripotent state or differentiated them to mesoderm cells. First we analysed SRF and ELK1 binding to chromatin and performed ChIP-quantitative PCR (qPCR) on regions which were bound by both ELK1 and SRF. Binding of both factors was specifically detectable on the known target genes EGR1 and EGR2 (Figure 4). Generally, we saw a decrease in SRF binding and a concomitant decrease in ELK1 binding in the same regions following SRF depletion (Figure 4A, C and Figure 5A, C). This pattern was detected in 19/19 of the regions tested H1-hESC (Figure 5A) and 18/22 of the regions tested in mesoderm (Figure 5C). This is consistent with the existing models, whereby SRF acts as a platform to aid ELK1 recruitment to chromatin (Gille et al., 1995; Janknecht & Nordheim, 1992; Latinicki et al., 1996; Treisman et al., 1992). Conversely, when we depleted ELK1 and performed ChIP-qPCR on regions which were bound by both ELK1 and SRF, we saw the expected decrease in ELK1 binding but a general increase in SRF binding in both H1-hESCs and mesoderm cells (Figure 5B, D). This pattern was detected in 16/19 of the regions tested H1-hESC (Figure 5B) and 16 of the 22 regions tested in mesoderm (Figure 5D). These results confirm a widespread role for SRF in stabilising ELK1 occupancy on chromatin but suggest an unexpected role for ELK1 in apparently reducing SRF occupancy on chromatin. Raw Fluidigm data are available on figshare (Prise, 2019d).

To investigate whether these changes in transcription factor binding correlated with gene expression, we again performed a knockdown of ELK1 in H1-hESCs or during mesoderm differentiation and tested the expression of a number of target genes. First, we assessed whether we could detect the known activating role of ELK1 at the immediate-early genes EGRI, EGR2 and EGR3 in these cells. As these genes are inducibly activated by ERK pathway signalling, we activated the ERK pathway by culturing mesoderm cells (derived from H1-hESCs) in DMEM/F12 media and then switched the media to MIM for 15 mins. This treatment caused increased levels of active, phosphorylated ERK (Figure 6A) and the activation of EGR1, EGR2 and EGR3 expression (Figure 6B). ELK1 was efficiently depleted by siRNA treatment (Figure 6A) and this depletion caused a significant decrease in the expression of EGR1, EGR2 and EGR3 under stimulating conditions (Figure 6B). Having established the known activating role of ELK1 in our system, we switched to investigating whether ELK1 plays an activating role at different genes which are not expected to be activated by the ERK pathway as exemplified by SPARCLI (Figure 6C). In both H1-hESC and mesoderm cells, ELK1 depletion caused an increase rather than a decrease in the expression of a panel of its target genes (Figure 6D, E). This indicates that ELK1 is necessary for the repression rather than the activation of these target genes.

ELK1 status does not affect the response to changes in actin dynamics

A plausible model is that SRF is an activator at these loci, and ELK1 would then act in a repressive manner to keep SRF activity in check. This model was previously proposed for the role of ELK1 in opposing the recruitment of the MRTF family co-activator myocardin in smooth muscle cells (Wang et al., 2004). Indeed, ELK1 and MRTFs occupy the same binding surface on SRF, meaning that binding is mutually antagonistic (Zaromytidou et al., 2006). If ELK1 was opposing the actions of MRTF family members, depletion of ELK1 would be predicted to hypersensitise target gene expression to activators of this pathway. To address this possibility, we tested the effect of ELK1 depletion in the context of cytochalasin D stimulation, which acts through inhibiting actin polymerisation and has been shown to activate SRF-target genes through the MRTFs (Essault et al., 2014; Posern & Treisman, 2006).

We stimulated serum-starved mesoderm cells with cytochalasin D, concurrently with ELK1 knockdown, and tested the expression of four target genes for the ELK1-SRF complex, EGR2, CDKN1A, FOSL1 and SPARCLI. Neither FOSL1 nor SPARCLI were responsive to cytochalasin D treatment under serum-starved conditions, suggesting a lack of involvement of MRTFs (Figure 7). As observed previously, we saw an increase in the expression of both genes upon ELK1 knockdown in mesoderm cells under both normal culture conditions and also when treated with cytochalasin D (Figure 7). However, these genes did not become responsive to MRTF pathway activation when the putative MRTF-binding inhibition via ELK1 was removed by ELK1 depletion (Figure 7). In contrast, EGR2, a gene usually activated by ELK1, is activated by cytochalasin D and this effect is potentiated by depletion of ELK1 (Figure 7). Thus,
Figure 3. The role of ELK1 in gene expression during mesoderm differentiation. (A and B) Reverse transcription-quantitative PCR (RT-qPCR) measuring the expression of pluripotency markers (A) or the mesoderm marker (T/Brachyury) after 72 of growth in MIM. (C) Western blots for ELK1, the indicated pluripotency markers, T/Brachyury, and the control TUBB protein in H1-hESC cells and H1-hESCs grown in MIM for 72 hours (mesoderm cells). (D) Western blots for ELK1, OCT4, SOX2, and TUB expression in H1-hESC cells treated with non-targeting (NT) siRNA or siRNAs targeting ELK1. (E and F) RT-qPCR measuring the expression of ELK1 and the indicated pluripotency markers (E) or the indicated ELK1-bound genes in H1-hESCs and H1-hESCs after 98 hours of growth in MIM (mesoderm cells) (F) after treatment with non-targeting (NT) siRNA or siRNAs targeting ELK1. RT-qPCR data are normalised to H1-hESCs in the presence of siNT and are the average of 3 independent experiments. *p-value < 0.05.
Figure 4. Reciprocal effects of ELK1 and SRF depletion on each other’s chromatin association. (A–D) Chromatin immunoprecipitation-quantitative PCR showing ELK1 and SRF binding (indicated above each graph) after treatment of H1-hESCs (A and B) or mesoderm cells (C and D) with non-targeting (NT) siRNA or siRNAs against SRF (A and C) or siELK1 (B and D). Binding to the promoter regions of EGR1 and EGR2 are shown and a negative control region located 2 kb upstream from the EGR1 locus. Data are the average of 3 independent experiments. *p-value < 0.05.
Figure 5. Inter-relationship between ELK1 and SRF binding to chromatin across co-bound loci. (A–D) Heatmaps of chromatin immunoprecipitation-quantitative PCR showing fold change in ELK1 and SRF binding after treatment of either H1-hESCs with siSRF (A) and siELK1 (B) or mesoderm cells after treatment of either H1-hESCs with siSRF (C) and siELK1 (D). Data are the average of three independent experiments. *p-value <0.05.

Figure 6. ELK1 is functions as an activator or a repressor at different target genes. (A) Western blot showing ELK1, phospho-ERK1/2 (P-ERK) and ERK2 expression in MIM-differentiated mesoderm cells treated with non-targeting (NT) siRNA or siRNAs targeting ELK1 and either starved of MIM or grown with stimulation by MIM addition for 15 mins. (B and C) Reverse transcription-quantitative PCR (RT-qPCR) showing the expression of control and ERK pathway activated genes (EGR1-3) (B) and an exemplar novel ELK1-SRF co-bound gene (C) in MIM-differentiated mesoderm cells treated with siELK1 and stimulated with MIM for 15 mins. Data are normalised to siNT treated cells (taken as 1) and are the average of 3 independent experiments. (D and E) RT-qPCR showing the expression of the indicated control genes (D) or genes co-bound by ELK1 and SRF (E) following treatment with non-targeting (NT) siRNA or siRNA directed against ELK1. Data are shown for H1-hESCs and differentiated mesoderm cells. Data are normalised to levels in H1-hESCs in the presence of siNT (taken as 1) and are the average of three independent experiments. *p-value <0.05.
ELK1 appears to interact differently with the MRTF pathway at different loci, but in regions where it acts as a repressor such as the SPARCL locus, it does so without influencing the response to this pathway. This suggests that binding by another co-activator or the intrinsic activity of SRF alone may be responsible for the increased gene activation we observe in the absence of ELK1.

Discussion

Previous work studying the role of ERK signalling in H1-hESC led to a focus on ELK1 as a potential regulator of pluripotency (Göke et al., 2013). In this context, ELK1 was proposed to act in combination with the PRC2 complex to repress the expression of genes involved in hESC differentiation. In line with this previous analysis on promoter proximal events, we demonstrated that ELK1 binding occupies two distinct modules throughout the genome, one enriched for the repressive PRC2 complex and one enriched for the presence of active histone marks and binding of the known ELK1 partner protein SRF. However, we were unable to demonstrate a repressive role for ELK1 through these elements indicating that ELK1 does not act in the context of PRC2-mediated repression. Instead, the widespread binding of ELK1 and the PRC2 complex appears to be coincidental rather than functionally linked (Figure 8A).

This led us to question whether ELK1 acts merely as a transcriptional activator rather than a repressor in hESCs, consistent with its known role as a mediator of ERK pathway-mediated gene activation (Gille et al., 1995; Janknecht et al., 1993; Marais et al., 1993). We confirmed that ELK1 acts as an activator of canonical target genes for the ELK1-SRF complex such as EGR1 (Figure 8C). However, we found that ELK1 loss broadly resulted in increased SRF ChIP signal at a panel of target genes for this complex, suggesting that it might act as a repressor in this context, perhaps by destabilising SRF binding to DNA. Indeed, we showed that ELK1 acts in a repressive manner at a
subset of target genes for this complex, as exemplified by FOSLI (Figure 8B). However, both ELK1 and SRF binding is detectable at this and other loci by ChIP-seq analysis, making it unlikely that ELK1 destabilises SRF binding. Moreover, previous studies have shown that ELK1 can stabilise SRF binding to DNA rather than inhibiting its binding (Ling et al., 1998). Others have previously shown that depletion of ELK1 along with other TCF subfamily proteins, results in increased ChIP signal for SRF at co-bound genes in murine cells, although they provided no molecular explanation for this phenomenon (Gualdrini et al., 2016). Instead, an alternative technical explanation might be increased epitope exposure on SRF after ELK1 knockdown, either through loss of steric hindrance or due to conformational changes in the DNA-bound SRF.

In theory, loss of ELK1 binding to SRF might reveal a binding surface for another co-activator protein as well as potentially allowing access to antibodies used in the ChIP procedure. Such a scenario would be consistent with the previously defined role for ELK1 in opposing binding by the MRTF family of co-activator proteins (Wang et al., 2004; Zaromytidou et al., 2006). However, loss of ELK1 did not generally make its target genes more responsive to MRTF pathway activation. Whilst our data do not support a role for MRTFs as an important co-activator in this context, it may be that an as-yet-unknown factor may play a role in SRF-mediated gene activation. Future studies are needed to address this possibility. Alternatively, ELK1 may itself impart repressive properties on an SRF-bound regulatory region, such as through recruitment of the SIN3A complex (Yang et al., 2001) or through SUMO-mediated recruitment of histone deacetylases (Yang & Sharrocks, 2004) as previously shown in other cell types. However, it is unclear why ELK1 should be repressive at only a subset of its binding regions and activating at others.

In summary, our work has identified a role for ELK1 in acting in its traditional role as a transcriptional activator downstream from the ERK pathway in hESCs. In addition, it also plays a repressive role in hESCs through SRF-bound regulatory regions. However, we were unable to find evidence to support a role in transcriptional repression in conjunction with the PRC2 complex as previously proposed (Göke et al., 2013). ELK1 therefore acts as dichotomous transcriptional regulator in hESCs, through imparting both activating and repressive activities to SRF-bound target genes.

Methods

Cell Culture

H1-hESC cells (Wicell) were routinely cultured in mTeSR1™ (StemCell Technologies). Plates were coated with Matrigel (Corning) at 37°C for 1 hour before passage. To passage the cells, the plates were coated with a thin layer of ReLeSR™ (StemCell Technologies) and incubated at 37°C for 5 minutes.

For shELK1 and RA treatment, conditioned H1 media was used, containing DMEM/F12 (Invitrogen), 20% (v/v) knockout serum replacement (Thermo Fisher Scientific), 1 mM L-glutamine (Gibco), 1% (v/v) nonessential amino acids (Gibco), 0.1 mM 2-mercaptoethanol (Gibco), and 4 ng/ml basic fibroblast growth factor (Invitrogen). This media was conditioned with CFI mouse fibroblasts (MTI-GlobalStem) for 24 hr prior to adding to the H1-hESCs. Media was then vacuum filtered (0.22 µM), and an additional 8 ng/ml of basic fibroblast growth factor (Invitrogen) was supplemented to conditioned medium before usage. To passage the cells, the cells were coated with a thin coat of dispase (StemCell Technologies) and incubated at 37°C for 5 minutes.

For differentiating hESCs to mesoderm, cells were first treated with 10 µM Y-27632 (ROCK inhibitor) for 1 hour before passage and dissociated with TrypLE™ Express (StemCell Technologies). Cells were initially seeded at a density of 5x10^5 per cm^2 in mTeSR1™ supplemented with 10 µM Y-27632. After 24 h, cells were grown in STEMdiff™ mesoderm Induction medium (StemCell Technologies) for an additional 3 days.

To activate the ERK signalling pathway, H1-hESCs were first allowed to differentiate into mesoderm cells, maintained in DMEM/F12 media lacking serum for 24 h and then switched the media to MIM for 15 mins for analysing ERK activation and 60 mins for studying gene expression. DMEM/F12 media was used as a control for MIM stimulation.

For retinoic acid (RA) treatment, cells were dissociated with TrypLE™ Express and seeded at a density of 5x10^5 per cm^2 in mTeSR1™ supplemented with 10 µM Y-27632. After 24 h, cells were grown in mTeSR1™ supplemented with 5 µM RA (Sigma) for up to 96 h. DMSO was used at a final concentration of 1:10,000 as a control for RA treatment.

For cytochalasin D stimulation, H1-hESCs were first allowed to differentiate into mesoderm cells, maintained in DMEM/F12 media lacking serum for 24 h and then switched to DMEM/F12 containing 2 µM cytochalasin D for 60 minutes to study gene expression. DMEM/F12 media containing DMSO at a final concentration of 1:10,000 was used as a control for cytochalasin D stimulation.

shRNA and siRNA treatment regimes

For shRNA treatment, cells were first treated with ROCK inhibitor and dissociated with TrypLE™ Express. Next, 5x10^5 cells were treated with 7.5 µl of TransIT®-LT1 (Mirus) plus 2.5 µg of shRNA plasmid prepared in 250 µl of OptiMEM. shELK1 plasmid was a pSuper-derived plasmid containing the shRNA hairpin for ELK1: 5’-GCCCAGAAGTTCGTCTACAA-3’ (Göke et al., 2013). An empty pSuper plasmid was used as a control for shELK1 treatments.

For siRNA transfection cells were prepared as above and after dissociation seeded at a concentration of 5x10^5 per cm^2 in mTeSR1™ supplemented with 10 µM Y-27632. Each 5x10^5 cell sample was treated with 7.5 µl Lipofectamine RNAiMAX reagent (Thermo Fisher Scientific) and 2.5 µl of siRNA (20 µM stock concentration), prepared in 150 µl Opti-MEM (Gibco). A non-targeting siRNA (siNT) was used as a control for siELK1 and siSRF treatments.
ChIP assays

Cells were incubated at room temperature with 1% (v/v) formaldehyde (Sigma), for 10 minutes (3×10^6 cells were seeded per immunoprecipitation (IP)). The crosslinking reaction was then quenched with 0.125 M glycine for 5 minutes. Cells were washed with ice cold 1x PBS. Next, 3×10^6 cells were harvested in FA cell lysis buffer (10 mM Tris-HCl, pH 8.0, 0.25% (v/v) Triton-X100, 10 mM EDTA, 0.1M NaCl) rotated for 10 minutes at 4°C, the nuclei pelleted at 13.1 krpm at 4°C for 5 minutes and the supernatant discarded. Cells were resuspended in FA Cell Lysis Buffer, rotated for 10 minutes at 4°C, pelleted at 13.1 krpm at 4°C for 5 minutes and the supernatant discarded. Nuclei were then resuspended in 1% SDS solution (50 mM HEPES-KOH, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% (v/v) Triton-X100, 0.1% (v/v) Na-DOC, 1% (w/v) SDS), rotated for 10 minutes at 4°C and the chromatin pelleted at 13.1 krpm at 4°C for 5 minutes and the supernatant discarded. Chromatin was then suspended in 0.1% SDS solution (50 mM HEPES-KOH, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% (v/v) Triton-X100, 0.1% (v/v) Na-DOC, 0.1% (w/v) SDS), rotated for 10 minutes at 4°C, pelleted at 13.1 krpm at 4°C for 5 minutes and the supernatant discarded. Chromatin was then resuspended in 0.1% SDS solution and sonicated to produce chromatin fragments of 100–500 bp.

For 3×10^6 cells, 12.5 µl of Dynabeads® Protein G (Thermo Fisher Scientific) and 1.25 µg of antibodies were conjugated at room temperature for 2 hours, after which, conjugated beads were washed with 0.1% SDS buffer. The lysate was then rotated with the conjugated beads overnight at 4°C. The next day, beads were washed sequentially with 0.1% SDS solution high salt wash (50 mM HEPES-KOH, pH 7.5, 500 mM NaCl, 2 mM EDTA, 1% (v/v) Triton-X100, 0.1% (v/v) Na-DOC, 0.1% (w/v) S DS), rotated for 10 minutes at 4°C and the chromatin pelleted at 13.1 krpm at 4°C for 5 minutes and the supernatant discarded. DNA was then further purified using the QIAquick PCR purification kit (Qiagen). For shELK1 and MIM treatment, DNA was then further purified using the QIAquick PCR purification kit (Qiagen). For Western blot analysis, cells were harvested in RIPA buffer by scraping on ice. Cell lysates were then centrifuged at 13.1 krpm at 4°C for 2 minutes. The supernatant was then measured using a Bradford Protein Assay. Next, 1 µl of sample was added to 1 ml of Coomassie Brilliant Blue (ThermoFisher Scientific) and 1.25 µg of antibodies (Thermo Fisher Scientific) and measured against BSA standards ranging from 0.2 mg/ml to 2 mg/ml. Approximately 20 µg of protein was used for each well. 1x SDS loading buffer was added to the lysate, which was then boiled at 99°C for 10 minutes. Proteins were resolved on the 12% gel in 1x SDS running buffer, and shaken at 69°C at 1000 rpm for 1 hour. This supernatant was then transferred to a new tube, treated with 1:50 Proteinase K (20 mg/ml) (Roche) and shaken at 55°C at 600 rpm for 1 hour. For siELK1 and MIM treatment, DNA was then further purified using the QIAquick PCR purification kit (Qiagen).

For MIM stimulation and siELK1 experiments, RNA was purified with an RNaseasy Kit (Qiagen) using the manufacturer’s protocol. For RA and shELK1 experiments, cells were collected into 350 µl of RNAzol (Sigma) homogenised with a Gilson pipette, and spun at 13.1 krpm at 4°C for 20 minutes The aqueous layer was then mixed 1:1 with isopropanol and RNA precipitated and dried as described for ChIP-isolated DNA above. cDNA was then prepared using SuperScript2 (Thermo Fisher Scientific) according to the manufacturer’s instructions (PCR was then carried out using Power SybrGreen (Thermo Fisher Scientific) with an annealing temperature of 55°C, according to the manufacturer’s instructions. Data was collected with the Viia7 (Thermo Fisher Scientific) and analysed with Viia7 V1.2 software (Thermo Fisher Scientific). The PCR primers are shown in Extended data, Supplementary Table S1 (Sharrocks, 2019).

RT-qPCR assays

For MIM stimulation and siELK1 experiments, RNA was purified with an RNaseasy Kit (Qiagen) using the manufacturer’s protocol. For RA and shELK1 experiments, cells were collected into 350 µl of RNAzol (Sigma) homogenised with a Gilson pipette, and spun at 13.1 krpm at 4°C for 20 minutes The aqueous layer was then mixed 1:1 with isopropanol and RNA precipitated and dried as described for ChIP-isolated DNA above. cDNA was then prepared using SuperScript2 (Thermo Fisher Scientific) according to the manufacturer’s instructions (PCR was then carried out using Power SybrGreen (Thermo Fisher Scientific) with an annealing temperature of 55°C, according to the manufacturer’s instructions. Data was collected with the Viia7 (Thermo Fisher Scientific) and analysed with Viia7 V1.2 software (Thermo Fisher Scientific). The PCR primers are shown in Extended data, Supplementary Table S1 (Sharrocks, 2019).

Western blotting

For Western blot analysis, cells were harvested in RIPA buffer by scraping on ice. Cell lysates were then centrifuged at 13.1 krpm at 4°C for 2 minutes. The supernatant was then measured using a Bradford Protein Assay. Next, 1 µl of sample was added to 1 ml of Coomassie Brilliant Blue (ThermoFisher Scientific) and measured against BSA standards ranging from 0.2 mg/ml to 2 mg/ml. Approximately 20 µg of protein was used for each well. 1x SDS loading buffer was added to the lysate, which was then boiled at 99°C for 10 minutes. Proteins were resolved on the 12% gel in 1x SDS running buffer, and transferred to a nitrocellulose membrane using transfer buffer. Finally, cells were incubated with primary and secondary antibodies (Extended data, Supplementary Table S2 (Sharrocks, 2019)), diluted 1:500–2000 and 1:10000, respectively, in Licor Odyssey Buffer and imaged on the Odyssey Imaging System (Licor biosciences).

Bioinformatics analysis

For ChIP-seq analysis from published datasets from human H1-hESCs (Extended data, Supplementary Table S3 (Sharrocks, 2019)), reads were mapped to the genome using Bowtie2 (v2.2.9) with default settings (Langmead & Salzberg, 2012). Bowtie2 output was then sorted, compressed and unaligned reads removed using samtools (v0.1.18), using the settings -Shu -F4, which removed unmapped reads (Li et al., 2009). Finally, peaks were called with MACS2, using the default settings (Zhang et al., 2008). To identify intersecting peaks from two datasets, after MACS2 peak calling, narrowPeak files were intersected with the intersectBed tool in bedtools (v2.21)(Quinlan & Hall, 2010), using the -f 0.1 and -r settings, creating a reciprocal overlap of 10%.

To create tag density graphs, the mapped, sorted and compressed ChIP-seq files were converted to BED files using the bamtobed
tool in bedtools. BED files were converted to tag directories using the makeTagDirectory.pl tool in HOMER (v4.8.3) (Heinz et al., 2010). Finally, ChIP-peaks were annotated using annotatePeaks.pl tool in HOMER, using the settings -size -2500, 2500 -hist 25 -norm 0, which created a tag density profile with a 25 bp bin, averaged to tag count in all tag directories, 2500 bp on either side of the peak centre.

To associate peaks to potential target genes we used the nearest gene model in HOMER (with default settings; Heinz et al., 2010). Enriched functional or biological processes associated with these genes were identified from lists of gene ontology (GO) terms using DAVID v6.7 (Huang et al., 2008; Huang et al., 2009).

Statistical analysis
Pairwise student’s t-tests were performed in GraphPad v7. Statistical significance determined using the Holm-Sidak method, with significance set to p < 0.05. Hypergeometric p-values were calculated using the phyper function in R v3.4.1

Data availability
Underlying data
Raw data underlying the findings of this study are available from figshare. These include raw GO data (Figure 1F, G: GO terms), RT-qPCR data (Figure 2A: RT-qPCR data for RA stimulation; Figure 2B, D-F: RT-qPCR data plus shELK1; Figure 3A: RT-qPCR data for pluripotency genes in hESCs and mesoderm cells; Figure 3E: RT-qPCR data for pluripotency genes plus siELK1; Figure 3F: RT-qPCR data for differentiation factor genes plus siELK1; Figure 6D: RT-qPCR data in mesoderm and hESCs plus siELK1; Figure 6B and C: RT-qPCR data for EGR1-3 plus/minus MIM stimulation; and Figure 7: RT-qPCR data with CytoD treatment), ChIP-qPCR data (Figure 2D: ChIP-qPCR data for ELK1 plus siELK1; Figure 2E: ChIP-qPCR data for SUZ12 plus siELK1), Fluidigm data (Figure 4 and Figure 5: ChIP-qPCR data plus siELK1 or siSRF), and uncropped western blots (Figure 2C, Figure 3C, D and Figure 6).


Extended data
Extended data are available from figshare.

Supplemental Table S1. Human H1-hESCs ChIP-seq data set accession numbers used in this study.

Supplemental Table S2. Antibodies used in the study.

Supplemental Table S3. Human H1-hESCs ChIP-seq data set accession numbers used in this study.

DOI: https://doi.org/10.6084/m9.figshare.7695617 (Sharrocks, 2019).

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Grant information
This work was funded by the A*STAR programme for PhD studentships with Manchester and Singapore for IP and a grant from the Wellcome Trust (grant 103857) to ADS.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements
We thank Karen Palmer and Mairi Challinor for excellent technical assistance; staff in the Genomic Technologies facility; Yun-Shen Chan and Huck Hui Ng for help and advice on hESC culture; Shen-Hsi Yang and members of our laboratory for comments on the manuscript and stimulating discussions.

References
Cruzalegui FH, Cano E, Treisman R: ERK activation induces phosphorylation of Elk-1 at multiple S/T/P motifs to high stoichiometry. Oncogene. 1999; 18(56): 7948–7957. Published Abstract | Publisher Full Text
Huang DW, Sherman BT, Lempicki RA: Systematic and integrative analysis of


Prise I: Raw Western Blots. figshare. Figure. 2019e. http://www.figshare.com/10.6084/m9.figshare.7565682.v1


In this paper, the authors evaluate the dual activating and repressive role of the ETS transcription factor ELK-1 in human embryonic stem cells. The paper builds upon a previous study (Göke et al. Molecular Cell 2013) in which ERK genome-wide chromatin interactions in human embryonic stem cells was characterized. In the present paper, the authors observed a significant overlap in ELK-1 and SUZ12 (PRC2 complex) binding regions but they don't find any evidence that ELK-1 does have a role in mediating transcriptional repression through these regions. Interestingly they find that ELK-1 has a repressive role during mesoderm differentiation that appears not to be exerted through competition with MRTF co-activators of RhoA-mediated gene expression. The paper represents an interesting follow up of the earlier work and is written in a clear and logical fashion. The purpose of the study is well defined and technically sound. However some data and aspects of the manuscript are worth clarifying.

Figure 1. My understanding is that ELK-1 binding motif is only enriched in the subset of ELK-1 binding sites that are co-occupied by ERK2 whereas promoters bound by ELK-1 without ERK2 (and thus with SUZ12 and EZH2) do not have this ELK-1 binding motif, at least for a 500bp window. Is this also the case with your 2500bp window? If true, do the authors have any explanation of how ELK-1 is recruited?

Figure 2A. The RT-qPCR experiments after retinoic acid (RA) treatment appear somewhat highly variable especially for PAX7 and POUF3F2. Do the authors identify more than the six ELK-1+SUZ12 bound genes whose expression increased upon RA treatment? If yes, it should be worth to include them. Is the expression of ELK-1 affected by RA?

Figure 3. The role of ELK-1 during mesoderm expression should be discussed in more detail. The authors nicely show that ELK-1 depletion caused an increase in the expression of FOXC1 and HAND2 (Figure 3F) but in the meantime the Western-blot (Figure 3C) suggests that ELK-1 protein expression is induced during mesoderm differentiation. Is this possible that these genes are ELK-1/PRC2- mediated repression dependent?

Figure 5. FOXC1 (in relation with RT-qPCR Figure 3F) is included in the heatmaps of chromatin Ip but not HAND2. If the ChiP-qPCR has been done for HAND2, it could be nice to add it.

References
1. Göke J, Chan YS, Yan J, Vingron M, Ng HH: Genome-wide kinase-chromatin interactions reveal the

**PubMed Abstract I Publisher Full Text**

**Is the work clearly and accurately presented and does it cite the current literature?**
Yes

**Is the study design appropriate and is the work technically sound?**
Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**
Yes

**Are all the source data underlying the results available to ensure full reproducibility?**
Yes

**Are the conclusions drawn adequately supported by the results?**
Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** ETS transcription factor family, regulation of gene expression

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

**Referee Report 12 March 2019**

https://doi.org/10.21956/wellcomeopenres.16464.r34992

**Ron Prywes**
Department of Biological Sciences, Columbia University, New York, NY, 10027, USA

The authors nicely evaluate the role of Elk1 in regulating gene expression in human embryonic stem cells. Elk1 co-binds to DNA with SRF, but can also bind DNA without SRF. They don’t find evidence that the sites bound without SRF are functional here. Interestingly, they find that Elk1 can function as an activator or a repressor depending upon the exact gene binding site they examine.

One conclusion that I feel is less well proven is that Elk1 repression is independent of its blocking another SRF co-factor MRTF-A and -B. Their evidence is that activation of MRTF-A/B by cytochalasin D is not stimulated after Elk1 knockdown. However, the activation of specific genes in these cells could be due to basal MRTF-A/B activation (or is the related myocardin gene expressed in these cells?). If so, perhaps there is something about these cells that limits cytochalasin activation of MRTF-A/B at these genes. A more thorough way to test this question is to knockdown the members of the MRTF family along with Elk1.
knockdown to see whether the derepression is affected.

Some more minor points:
1. In Figure 6, different cell treatments are used in 6B and 6D, E. The differences are not entirely clear. In 6B, there is a brief treatment of MIM media. What is done in the other figures? This is important as in 6B, Elk1 activates expression and in 6E it represses.
2. It's concluded for Fig. 6, on page 6, that Elk1 represses specific genes. This implies that it is doing so directly by binding to them. What rules out an indirect effect? This should at least be discussed.
3. In Figure 2, the authors examine retinoic acid induction of the cells and conclude that Elk1 binding to PRC2 is not important. Later in the paper they use media to induce the cells to differentiate to mesodermal cells. Is it possible that Elk1/PRC2 target genes are important for this type of induction of these cells?
4. We previously found that Elk1 could act as a repressor of MRTF target genes in NIH3T3 cells particularly when grown continuously and found a redundancy for immediate early activation of some genes by Elk1 and MRTF. Are the embryonic stem cells different than other cell types for Elk1 activity and does the growth state of the cells affect Elk1 activity?

References

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Cell signaling

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.